Skip to Main Content

Advertisement

Current Issue
Volume 4,
Issue 9,
May 12, 2020

Featured Content


A user guide to the American Society of Hematology clinical practice guidelines

Blood Advances has been proud to publish a series of Clinical Guidelines prepared from subcommittees organized by the American Society of Hematology. Izcovich and colleagues developed a user guide to the clinical practice guidelines that we hope you find informative and useful.


Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

It has been recognized for some time that the Wnt pathway plays an important role in stem cell biology and the ability of cancer cells to self-replicate. Lee and colleagues explored the first human experience of CWP291, an inhibitor of the Wnt pathway, in the treatment of acute myeloid leukemia and myelodysplastic syndrome.


Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, for Hematologic Malignancies

The costimulatory molecule CD27 is an attractive target for the treatment of hematological malignancies. Ansell and colleagues explored the CD27 agonist varlilumab in a phase 1 dose escalation study with interesting findings and some evidence of clinical benefit.


Adult T-cell leukemia/lymphoma incidence rate in French Guiana: a prospective cohort of women infected with HTLV-1

Adult T-cell leukemia/lymphoma is an aggressive malignancy caused by the human T-cell leukemia virus (HTLV-1). It is generally not known what the incidence of this challenging disease is amongst HTLV-1 carriers. In this issue’s Global Advances manuscript, Ramassamy and colleagues followed a cohort of women in French Guiana prospectively for over 25 years. This important study helped define the risk of HTLV-1 infection progressing to full-blown leukemia/lymphoma in an at-risk population over time.


Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

Recent studies have identified the role of isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia. Ivosidenib, a targeted IDH1 inhibitor, results in clinical responses in some patients with this mutation. Cheo and colleagues explored the molecular mechanisms mediating relapse following ivosidenib therapy.


Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases

Allogeneic hematopoietic cell transplantation is used for the treatment of a broad array of nonmalignant conditions, especially in children. Satwani and colleagues explored the risk of subsequent malignancies and late mortality, using the CIBMTR database. The study documented that the risk of these complications is relatively low in these patients but still significantly higher than in the general population.

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement

X